President-elect Trump announced Tuesday that his choice for deputy secretary of Health and Human Services is Jim O'Neill, a close historical associate of investor and billionaire Peter Thiel. .
“I am very pleased to nominate Jim O'Neill to serve as Deputy Secretary of Health and Human Services, working alongside Robert F. Kennedy Jr.,” President Trump said in a statement Tuesday. “He will oversee all operations and improve governance, transparency, and accountability to make America healthy again.”
President Trump also said in a statement that O'Neal and Kennedy will “work together to help all Americans, especially our most precious resource, our children, live long and healthy lives and make America great and healthy again.” We will unite in our fight against this,'' he said.
washington post reported on Monday Regarding President Trump's desire to nominate Mr. O'Neill as Deputy Secretary of HHS.
Bloomberg reported that the president-elect had previously considered O'Neill for the role of head of the Food and Drug Administration (FDA) for the start of his first administration in late 2016.
Mr. O'Neill also served as managing director of Teal's Mithril Capital Management and principal deputy assistant secretary of the Department of Health and Human Services under the administration of former President George W. Bush.
In a 2014 speech, O'Neill called for opposition to the FDA's mandate to consider drug efficacy in drug approval decisions. He said authorities should only consider drug safety.
“The FDA should be reformed so that sponsors can prove safety before approving drugs, and people can start using them at their own risk, but without too much of a safety risk,” O'Neill said. said. “But let’s prove its effectiveness once it’s legalized.”
Experts expressed concern about his comments, saying they showed a lack of knowledge about the FDA's review process and that it was impossible to differentiate between safety and efficacy issues.
